



(51) International Patent Classification:

C07D 211/88 (2006.01) **C07D 471/04** (2006.01)
C07D 401/12 (2006.01) **C07D 498/04** (2006.01)
C07D 405/04 (2006.01) **C07D 513/04** (2006.01)
C07D 405/12 (2006.01) **A61P 35/00** (2006.01)
C07D 405/14 (2006.01) **A61P 37/00** (2006.01)
C07D 413/12 (2006.01) **A61K 31/4545** (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:

PCT/US2024/039292

(22) International Filing Date:

24 July 2024 (24.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/528,823 25 July 2023 (25.07.2023) US

(71) Applicant: MONTE ROSA THERAPEUTICS, INC.

[US/US]; 321 Harrison Avenue, Suite 900, Boston, Massachusetts 02118 (US).

(72) Inventors: **LIARDO, Elisa**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **MCALLISTER, Laura Ann**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **WIEDMER, Lars**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH). **RASMUSSEN, Timothy**; 321 Harrison Avenue, Suite 900, Boston, 02118 (US). **FASCHING, Bernhard**; 321 Harrison Avenue, Suite 900, Boston, 02118 (US). **CABRÉ, Xavier Lucas**; Klybeckstrasse 191, WKL-136.3, 4057 Basel (CH).

(74) Agent: **GUTIERREZ, Gregory D.**; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION




FIG. 1A

(57) **Abstract:** This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and/or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (e.g. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (e.g. anemia of inflammation) and eye disorders (e.g. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*